ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1433

Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis

Yoshikazu Ogawa1, Nobunori Takahashi 2, Toshihisa Kojima 2 and Naoki Ishiguro 2, 1Nakatsugawa Municipal General Hospital, Nakatsugawa, Japan, 2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid Factor and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Treatments Poster II: Established Treatments

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Discontinuation of biologic therapy in rheumatoid arthritis is attributable to various reasons, with the most important cause being insufficient response. In this study, we investigated the association between rheumatoid factor (RF) and anti–citrullinated protein autoantibody (ACPA) status and the discontinuation of tumor necrosis factor inhibitors (TNFi) therapy due to ineffectiveness in bio-naïve rheumatoid arthritis (RA) patients.

Methods: This study included patients enrolled in the Tsurumai Biologic Communication Registry in Japan. The crude comparison of TNFi discontinuation due to insufficient response between seropositive and seronegative patients was analyzed using the cumulative incidence function of competing events and Gray test. We assessed the associations between baseline characteristics and discontinuation of TNFi treatment due to insufficient response using Fine-Gray proportional hazard regression. Fine-Gray proportional hazard analysis considered competing events of interest, including insufficient response, adverse event, palliation, and personal reasons.

Results: Of 1237 patients evaluated, 79.3% were positive for RF and 85.4% for ACPA; 72.6% were double positive and 11.1% were double negative. TNFi therapy had been discontinued because of insufficient response at 200 weeks in 19.8% RF-positive, 16.7% RF-negative, 23.0% ACPA-positive, and 13.8% ACPA-negative patients. There was a significantly higher discontinuation rate due to insufficient response in ACPA positive patients than in ACPA negative patients using Gray test, with a similar trend as that for RF status. RF positivity was significantly predictive of the discontinuation of TNFi treatment due to insufficient response using Fine-Gray proportional hazard regression analysis after adjusting for baseline characteristics, including age, sex, stage, class, disease activity at baseline, methotrexate use, and prednisolone use (hazard ratio 1.73 [95% confidence interval 1.07–2.80]).

Conclusion: Using Fine-Gray proportional hazard regression, we demonstrated that RF positivity was related to a higher discontinuation rate of TNFi treatment due to insufficient response in bio-naïve RA patients.

Figure. Cumulative incidence of competing events and Gray test.
A. Discontinuation of tumor necrosis factor inhibitors therapy due to ineffectiveness, stratified by rheumatoid factor -RF- status -P = 0.14 by Gray test-.
B. Discontinuation of tumor necrosis factor inhibitors therapy due to ineffectiveness, stratified by anti-citrullinated protein antibody -ACPA- status -P < 0.05 by Gray test-.


Table 1


Table 2


Disclosure: Y. Ogawa, None; N. Takahashi, Abbvie, 8, Astellas Pharma, 8, Bristol-Myers Squibb, 8, Chugai Pahrmaceutical, 8, Eisai, 8, Janssen Pharmaceutical, 8, Pfizer, 8, Takeda Pharma, 8, Tanabe Mitsubishi Pharma, 8, UCB, 8; T. Kojima, AbbVie, 2, 8, Abbvie, 8, Astellas, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO., LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eli Lilly, 2, 8, Janssen, 2, 8, Janssen Pharmaceutical, 8, Lilly, 2, 8, Mitsubishi Tanabe, 2, 8, Novartis, 2, 8, Pfizer, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 8; N. Ishiguro, AbbVie, 2, 8, Abbvie, 2, 8, Asahi Kasei, 2, 8, Astellas, 2, 8, Astellas Pharma, 2, 8, Bristol-Myers Squibb, 2, 8, Chugai, 2, 8, Chugai Pahrmaceutical, 2, 8, Chugai Pharmaceutical CO.,LTD., 2, 8, Daiichi-Sankyo, 2, 8, Eisai, 2, 8, Eli Lilly, 2, 8, Janssen Pharmaceutical, 8, Kaken, 2, 8, Lilly, 8, Medical Corporation Sanjinkai, 2, 5, 8, Medical Corporation Toukoukai, 2, 5, 8, Mitsubishi Tanabe, 2, 8, Ono, 2, 8, Otsuka, 2, 8, Pfizer, 2, 8, Taisho Toyama, 2, 8, Takeda, 2, 8, Tanabe Mitsubishi Pharma, 2, 8, UCB, 8, Zimmer Biomet, 2, 8.

To cite this abstract in AMA style:

Ogawa Y, Takahashi N, Kojima T, Ishiguro N. Association Between Seropositivity and Discontinuation of Tumor Necrosis Factor Inhibitors Due to Insufficient Response in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/association-between-seropositivity-and-discontinuation-of-tumor-necrosis-factor-inhibitors-due-to-insufficient-response-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-between-seropositivity-and-discontinuation-of-tumor-necrosis-factor-inhibitors-due-to-insufficient-response-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology